Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension

Lorenz, Katrin; Rosbach, Klaus; Matt, Andreas; Pfeiffer, Norbert

doi:10.2147/opth.s25987

Cited by 6 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 As many as 50% of patients in the Ocular Hypertension Treatment Study required additional ocular hypotensive medications to maintain IOP reduction after the first year of treatment. 4 Although the safety and efficacy of adding a fixed-combination medication containing timolol to prostaglandin monotherapy have been demonstrated, 5, 6, 7 data are needed to evaluate the addition of a fixed combination without a β -blocker to PGAs.…”

Section: Introductionmentioning

confidence: 99%

Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial

Fechtner

Myers

Hubatsch

et al. 2016

Eye

View full text Add to dashboard Cite

PurposeTo determine whether intraocular pressure (IOP) lowering with fixed-combination brinzolamide/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA) was superior to that of vehicle+PGA in patients with open-angle glaucoma or ocular hypertension who were inadequately controlled with PGA monotherapyMethodsThis 6-week, multicenter, randomized, double-masked, parallel-group trial was conducted at 30 clinical sites in the United States between October 2013 and May 2014. Eligible patients were adults with open-angle glaucoma or ocular hypertension and with mean IOP ≥21 and <32 mm Hg, whereas receiving an open-label PGA (latanoprost, bimatoprost, or travoprost). Patients instilled a PGA once-daily in a run-in phase before randomization to masked BBFC or vehicle adjunctive treatment. Masked treatments were instilled 3 times daily for 6 weeks, and patients continued once-daily use of their PGA. The primary efficacy end point was the between-group difference in mean diurnal IOP (average of 0800, 1000, 1500, and 1700 hours time points) at week 6.ResultsAt week 6, mean diurnal IOP with BBFC+PGA was lower than with vehicle+PGA (17.1±0.4 mm Hg vs 20.5±0.4 mm Hg; between-group difference, −3.4±0.5 mm Hg; P<0.0001; 95% confidence interval, −4.5 to −2.4 mm Hg). BBFC+PGA reduced mean diurnal IOP by 5.7 mm Hg (25%) from the baseline IOP achieved with PGA monotherapy.ConclusionsTherapy with BBFC produced an additive IOP-lowering effect compared with a PGA alone or in conjunction with vehicle. BBFC may provide an effective treatment option for patients receiving PGA monotherapy who require additional IOP reduction.

show abstract

Section: Introductionmentioning

confidence: 99%

Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial

Fechtner

Myers

Hubatsch

et al. 2016

Eye

View full text Add to dashboard Cite

show abstract

“…Исследование состояло из 3 визитов: скрининговый и наблюдательные -спустя 4 нед (±3 дня) и 12 нед (±3 дня). На скрининговом визите пациентам объясняли необходимость продолжения местных инстилляций препарата латанопроста в прежнем режиме и добавления нового препарата (фиксированная комбинация бринзоламида и тимолола), инстиллируемого дважды в день приблизительно в 8 ч утра и 8 ч вечера, указана необходимость не менее чем 5 Полученные результаты соответствуют данным о добавочной эффективности фиксированной комбинации бринзоламида и тимолола, описанным в литературе [10,14].…”

Section: материал и методыunclassified

“…Фармакотерапию глаукомы обычно начинают с одного гипотензивного препарата: часто в качестве монотерапии первого выбора назначают аналоги простагландинов (АПГ) или β-блокаторы из-за их эффективного снижения ВГД и хорошей переносимости [8][9][10].…”

unclassified

“…Для пациентов с недостаточным контролем ВГД с помощью одного препарата добавление дополнительной фиксированной комбинированной терапии к монотерапии обеспечивает эффективность снижения ВГД с применением всего 2 флаконов (по сравнению с 3 отдельными препаратами). Рекомендации по лечению глаукомы предполагают поэтапное добавление одного гипотензивного препарата для пациентов, которым требуется дополнительное снижение ВГД [10,14], тем не менее добавление комбинированного препарата к монотерапии, как сообщается, имеет хороший профиль эффективности и безопасности [15].…”

unclassified

See 1 more Smart Citation

Adjunctive antihypertensive therapy of primary glaucoma with a fixed combination drug of 1% brinzolamide and 0.5% timolol: efficacy and safety

Petrov

Kalinina

Yakubova

et al. 2023

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

Purpose: a comparative study of the efficacy and safety of the combination drug Brinzopt Plus and the original drug Azarga used as adjunctive therapy in patients with primary open-angle glaucoma (POAG) previously treated with latanoprost.Material and methods. 30 patients (42 eyes) with advanced and far advanced POAG were randomly divided into 2 groups of equal size. The patients of the main group (21 eyes) received Brinzopt Plus, those of the control group had the original drug Azarga, one instillation 2 times a day. The target points were intraocular pressure (IOP), visual acuity, perimetric indices (MD, PSD), mean retinal nerve fiber layer thickness, minimal neuroretinal rim width, retinal nerve fiber layer thickness in the macula, ganglion cell layer thickness in the macula, inner plexiform layer thickness, as well as the number of adverse events. The observation period was 12 weeks. IOP was measured at 4 and 12 weeks.Results. After 2 weeks, both groups showed a statistically significant decrease in IOP, which remained stable after 4 and 12 weeks. The average decrease in IOP in Brinzopt Plus recipients was 25% and revealed no statistically significant differences with the original drug at any control point. A positive dynamic of visual acuity, static perimetry and optical coherence tomography values, which showed no significant intergroup differences, was recorded. Among the adverse events, manifestations of mild local discomfort were recorded in 4 out of 15 patients of the main group and in 3 out of 15 patients of the control group. No serious or systemic adverse events were noted.Conclusion. Brinzopt Plus has an efficacy comparable to the original drug and a favorable safety profile.

show abstract

“…Местная гипотензивная терапия остается предпочтительным стартовым лечением из-за благоприятного профиля риска и пользы [9]. Фармакотерапию глаукомы обычно начинают с одного гипотензивного препарата: часто в качестве монотерапии первого выбора назначают аналоги простагландинов (АПГ) или -блокаторы из-за их эффективного снижения ВГД [10][11][12].…”

unclassified

Efficiency and safety of the fixed latanoprost/ dorzolamide combination in open-angle glaucoma hypotensive treatment

Neroev,

Petrov,

Zhuravleva

et al. 2023

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

Purpose: to determine the efficacy and safety of fixed latanoprost/dorzolamide combination Dorzoprost in hypotensive treatment of primary open-angle glaucoma (POAG) patients previously treated with latanoprost.Material and methods. An observational study included 30 patients (37 eyes) with moderate and advanced POAG who had uncompensated elevated IOP receiving latanoprost monotherapy. During the screening visit, latanoprost was switched to Dorzoprost instilled once in the evening. The targets were IOP, visual acuity, MD and PSD perimetry indices, retinal nerve fiber layer thickness, minimum width of the neuroretinal rim, macula retinal nerve fiber layer thickness, and adverse events. The observation period lasted 12 weeks. IOP was measured at weeks 4 and 12.Results. After 4 weeks, a statistically significant decrease in IOP was noted, which remained stable at 12 weeks. The average additional IOP decrease of those treated with Dorzoprost was 17%. Statistically insignificant positive changes were registered in visual acuity, static perimetry and optical coherence tomography. By the end of the observation period, 6 cases revealed a decrease in the degree of conjunctival hyperemia, while all dry eye syndrome cases (5 patients) showed a decrease in the severity of the signs of the syndrome.Conclusion. Dorzoprost has a significant additive hypotensive effect and a favorable safety profile.

show abstract

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension

Cited by 6 publications

References 9 publications

Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial

Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial

Adjunctive antihypertensive therapy of primary glaucoma with a fixed combination drug of 1% brinzolamide and 0.5% timolol: efficacy and safety

Efficiency and safety of the fixed latanoprost/ dorzolamide combination in open-angle glaucoma hypotensive treatment

Contact Info

Product

Resources

About